Buprenorphine injection to the stellate ganglion in the treatment of upper body chronic pain syndromes

We failed to show a superiority of GLOA over SSB. Our results suggest it unlikely that the clinically observed effect after a single GLOA injection is due to a specific action of buprenorphine at the stellate ganglion. The efficacy of GLOA is hereby questioned. The use of GLOA in patients with cardiomyopathy should be cautioned. Trial registration: ISRCTN59287260; http://www.controlled-trials.com/